Protalix BioTherapeutics Inc. (DE) (PLX): Share Price, Stock Analysis, Annual Report | Value Research Get Protalix BioTherapeutics Inc. (DE) (PLX)'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house.
info-circle
company-logo

Click to see a quick summary and important updates about this stock!Dismiss

  • Healthcare •
  • Biotechnology & Pharma Research

Protalix BioTherapeutics Inc. (DE) (PLX)

NYSE: PLX

  • Market Capitalisation info

    $56 Mln

  • 12 Month Earnings info

    $-24 Mln

  • Price to Earnings info

    --

NYSE

$1.23

As on 12-Aug-2022 15:59 EDT

up-down-arrow $-0.01 • -0.41%

  • Prev Close info

    $1.23

  • Day's Openinfo

    $1.21

  • Today's Highinfo

    $1.24

  • Today's Lowinfo

    $1.21

  • Today's Volumeinfo

    99,145

Stock Performance
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Protalix BioTherapeutics Inc. (DE) (PLX)
47.29 10.86 17.79 -19.41 -19.17 -26.13 -31.92
S&P BSE Sensex
2.08 9.32 9.94 9.05 16.53 13.76 12.97
S&P Small-Cap 600
-8.13 14.13 12.23 -5.78 11.43 9.16 11.05
As on 12-Aug-2022
2021
2020
2019
2018
2017
2016
2015
Protalix BioTherapeutics Inc. (DE) (PLX)
-77.09 10.67 5.47 -52.76 48.54 -56.37 -44.57
S&P Small-Cap 600
25.27 9.57 20.86 -9.70 11.73 24.74 -3.36
S&P BSE Sensex
21.99 15.75 14.38 5.87 27.91 1.95 -5.03

Valuation
Stock
Peer Median

Growth & Efficiency
Stock
Peer Median

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

View Details arrow

Peer Comparison

search
search
search
search
    Comparison Details arrow

    Valuation Chart

        Financials

        View Details arrow

        Shareholding Pattern

        View Details arrow

        Other Details

        Pres, CEO & Director

        Mr. Dror Bashan

        Sr. VP, CFO, Treasurer & Corp. Sec.

        Mr. Eyal Rubin M.B.A.

        Headquarters

        Hackensack, NJ

        Website

        https://www.protalix.com
        More Details arrow
        Edit edit

        Key Facts

        • Market cap info

          $55.53 Mln

        • Revenue (TTM) info

          $43.12 Mln

        • Earnings (TTM) info

          $-24.39 Mln

        • Cash info

          $32.92 Mln

        • Total Debt info

          $33.40 Mln

        • Insider's Holding

          19.46%

        • Liquidity info

          Low

        • 52 Week range info

          $0.70 - 2.00

        • Shares outstanding info

          47,063,300

        • 10 Years Aggregate:

          CFO: $-189.17 Mln

          EBITDA: $-220.92 Mln

          Net Profit: $-204.79 Mln

        About The Company

        • Business

          Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

        • IPO Date

          15-May-1998

        • Pres, CEO & Director

          Mr. Dror Bashan

        • Sr. VP, CFO, Treasurer & Corp. Sec.

          Mr. Eyal Rubin M.B.A.

        • Listing info

          NYSE: PLX

        • Country

          United States

        • Headquarters info

          Hackensack, NJ

        • Website info

          https://www.protalix.com

        Share Download Stock Report
        share-icon Download Stock Report
        share-icon